Showing results (1871-1880 of 1,960) with videos related to

Sort By:
Pageof 196
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
NAM Journal|June 29, 2026
Highlighting best practices to advance next-generation risk assessment of cosmetic ingredientsEric Vaillancourt, Alaa Afdal Mohamed, Jay Ansell, et al.
American Journal of Hematology|July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphomaMatthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
American Journal of Hematology|September 3, 2025
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed TherapiesSuheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, et al.
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood|July 5, 2011
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomasThomas E Witzig, Hui Tang, Ivana N M Micallef, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trialsC S Tam, P Kapoor, J J Castillo, et al.
Blood Cancer Discovery|July 16, 2025
IRF4 promotes immune evasion and shapes the tumor microenvironment in Follicular LymphomaSurendra Dasari, Kerstin Wenzl, Geoffrey M Nelson, et al.
The New England Journal of Medicine|December 12, 2017
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's LymphomaJoseph M Connors, Wojciech Jurczak, David J Straus, et al.
Pageof 196